This study was supported by a grant from the Natural Science Foundation of Hubei Province (No. 2002AB 116).
Background Studies have confirmed that angiotensin II receptor blocker (ARB) and angiotensin converting enzyme inhibitors (ACEI) in the treatment of diabetic nephropathy (DN) has special advantages. We observed ...